The NMP22® BladderChek® Test is the only in-office test approved by the FDA as an aid in the diagnosis and management of bladder cancer. The NMP22 BladderChek Test is a painless and non-invasive assay, performed on a single urine sample, that detects elevated levels of NMP22 protein. Healthy individuals generally have very small amounts of NMP22 protein in the urine. However, the level of NMP22 protein is often elevated in the urine of patients with bladder cancer, even at early stages of the disease. The test can be performed in a physician’s office with results delivered during the patient visit, allowing a rapid, accurate and cost-effective way to aid in the detection of bladder cancer in patients at risk.

For ordering information contact:
Inverness Medical Innovations
North America, Inc.
(877) 441-7440
M - F, 8:00 AM - 8:00 PM EST

Urology product questions:
POC Sales Group
(866) 563-5518

Non-urology physician offices call:
(866) 563-5519

Package Inserts

NMP22® BladderChek® Test

NMP22® Test Kit

NMP22® BladderChek® Control Kit

NMP22® Urine Collection Kit/Vials